Ottimo Pharma
Ottimo Pharma is a private biotech company focused on developing bifunctional medicines aimed at extending the lives of individuals with cancer. The company is advancing its lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody designed for multiple solid tumor indications. Ottimo Pharma is also working on a pipeline of follow-on bifunctional assets to further its mission in oncology therapeutics.
Leadership & Board
- Current Number of Employees
- 20
- Current LinkedIn Followers
- 5,988
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $140M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $140M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Employee Trend
Ottimo Pharma had 20 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Ottimo Pharma had 5,988 followers as of October 12, 2026. The number of followers increased by 5 (0.08%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series A | $140.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| OrbiMed | Series A |
| Samsara BioCapital | Series A |
| Avoro Capital | Series A |
| Medicxi | Series A |
Similar Companies
A snapshot of private companies similar to Ottimo Pharma, helping you discover and navigate related company profiles.
Related News and Analysis
